Biomarker Discovery
Find molecular signatures that distinguish patient groups from high-dimensional omics data.
RNA-seq counts + clinical metadata
- Candidate biomarkers with multi-method consensus
- Effect sizes with confidence intervals
- Cross-validation and reproducibility metrics
Prioritize candidates for validation assays based on statistical rigor and biological plausibility.
Mechanism of Action
Understand how a treatment affects biological pathways and molecular processes.
Treated vs. control omics data
- Affected pathways ranked by enrichment significance
- Dose-response patterns where applicable
- Cross-pathway interaction mapping
Identify on-target and off-target effects to inform lead optimization or safety assessment.
Patient Stratification
Identify molecularly distinct subgroups within a clinical cohort.
Multi-omics + clinical outcomes data
- Subgroup definitions with molecular features
- Survival analysis across subgroups
- Distinguishing features for each stratum
Define inclusion criteria for enrichment trials or identify subpopulations for targeted therapies.
Cross-Study Meta-Analysis
Combine findings across multiple datasets to identify replicated signals.
Two or more public or internal datasets
- Replicated molecular signatures across studies
- Cross-study concordance metrics
- Heterogeneity assessment for each finding
Demonstrate reproducibility across independent cohorts before committing validation resources.
Target / Pathway Prioritization
Rank candidate targets by integrating multi-evidence scoring from omics and literature.
Omics data + literature context
- Prioritized target list with composite scores
- Pathway enrichment analysis
- Druggability and tractability annotations
Focus downstream validation on targets supported by convergent molecular evidence.
Toxicogenomics & Safety
Evaluate compound safety profiles by detecting organ-specific toxicity signals and distinguishing true liabilities from expected pharmacology.
Proteomics or transcriptomics from treated vs. control samples
- Overall toxicology assessment with confidence level
- Organ system safety profiles (hepatic, renal, pancreatic, cardiovascular)
- Favorable and unfavorable marker identification with statistical evidence
Prioritize compounds with cleaner safety profiles and flag liabilities requiring monitoring before advancing.